| Budget Amount *help |
¥46,670,000 (Direct Cost: ¥35,900,000、Indirect Cost: ¥10,770,000)
Fiscal Year 2023: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2022: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2021: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2020: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2019: ¥28,470,000 (Direct Cost: ¥21,900,000、Indirect Cost: ¥6,570,000)
|
|---|
| Outline of Final Research Achievements |
Retinitis pigmentosa is a representative disease of the retina, which eventually leads to blindness. The therapy of this disease has not yet been developed. Regenerative medicine and other therapies have been being developed, but their effectiveness depends on the condition of the patient's retina. Studies on animal models of the disease have shown that abnormal autonomic neural activity is observed in the diseased retina. In order to understand the patient retinal condition, we clarified the mechanism of the abnormal autonomic neural activity by which the diseased neural activity occurs by means of electro-physiological experiments, histological analysis, and mathematical model simulations.
|
